Skip to main content

Table 4 Unadjusted survival rates in overall and resected pancreatic cancer patients diagnosed in 2003–2005, 2006–2008, and 2009–2011

From: Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study

Survival Period Stage USA The Netherlands Belgium Norway Slovenia
Overall Resected Overall Resected Overall Resected Overall Resected Overall Resected
OS (95% CI)a OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI)
1 month 2003–2005 I–II 83 (82–84) 95 (94–96) 89 (87–91) 96 (93–97) 94 (92–96) 97 (94–98) 91 (88–94) 99 (94–100) 89 (84–93) 96 (90–98)
III–IV 61 (60–62) 86 (82–89) 73 (71–75) 88 (74–95) 88 (85–90) 96 (86–99) 78 (75–80) 100 (100–100) 69 (65–74) 92 (71–98)
2006–2008 I–II 84 (84–85) 96 (95–96) 92 (91–94) 97 (95–98) 95 (94–97) 97 (95–98) 90 (83–96) 99 (93–100) 93 (88–96) 99 (93–100)
III–IV 62 (61–63) 89 (86–91) 77 (75–78) 100 (100–100) 86 (85–88) 98 (91–99) 79 (76–81) 96 (75–99) 75 (71–78) 97 (80–100)
2009–2011 I–II 86 (85–87) 96 (96–97) 92 (90–93) 97 (96–98) 96 (95–97) 98 (97–99) 94 (91–96) 98 (95–99) 90 (85–94) 99 (94–100)
III–IV 63 (62–64) 90 (88–92) 76 (75–78) 91 (81–96) 85 (84–87) 100 (100–100) 78 (75–80) 96 (77–100) 75 (72–79) 98 (86–100)
Percent unit change,b P I–II + 3, 0.006 + 2, 0.004 + 3, 0.021 + 1, 0.257 + 2, 0.116 + 1, 0.577 + 3, 0.175 –1, 0.473 + 1, 0.851 + 4, 0.083
III–IV + 2, 0.002 + 4, 0.989 + 3, 0.001 + 3, 0.635 –2, 0.086 +4, 0.189 + < 1, 0.972 −4, 0.301 + 6, 0.024 + 6, 0.229
3 months 2003–2005 I–II 72 (71–73) 91 (90–92) 74 (71–76) 92 (89–94) 86 (83–89) 93 (90–96) 76 (71–80) 98 (93–99) 76 (69–82) 87 (79–92)
III–IV 42 (41–43) 74 (69–78) 42 (40–43) 84 (69–92) 66 (62–69) 93 (82–97) 44 (41–47) 87 (68–95) 36 (31–40) 58 (36–75)
2006–2008 I–II 73 (72–74) 92 (91–92) 78 (76–81) 93 (91–95) 87 (85–89) 92 (90–94) 72 (67–76) 94 (86–97) 80 (73–86) 92 (85–96)
III–IV 44 (43–44) 79 (76–82) 46 (44–47) 98 (88–100) 63 (61–65) 85 (95–91) 48 (46–51) 84 (63–94) 43 (39–47) 85 (67–93)
2009–2011 I–II 76 (75–77) 93 (92–94) 80 (78–82) 93 (91–95) 89 (87–91) 94 (92–96) 82 (78–85) 96 (92–98) 76 (70–82) 97 (91–99)
III–IV 45 (44–46) 81 (78–84) 45 (43–46) 85 (74–92) 63 (60–65) 93 (85–96) 47 (44–49) 86 (66–94) 44 (40–48) 76 (61–86)
Percent unit change,b P I–-II + 4, < 0.001 + 2, < 0.001 + 6, 0.001 + 1, 0.546 + 3, 0.118 + 1, 0.508 + 6, 0.035 − 1, 0.562 + < 1, 0.909 + 10, 0.005
III–IV + 3, < 0.001 + 7, 0.017 + 3, 0.001 + 1, 0.831 −3, 0.087 – < 1, 0.972 + 3, 0.225 −1, 0.890 + 8, 0.007 + 18, 0.085
12 months 2003–2005 I–II 38 (36–39) 64 (62–66) 33 (30–36) 64 (59–68) 52 (48–57) 62 (56–67) 34 (29–39) 66 (57–74) 38 (30–45) 51 (41–60)
III–IV 11 (11–12) 34 (29–39) 8 (7–9) 49 (33–63) 19 (17–22) 45 (31–57) 8 (6–10) 37 (20–53) 5 (3–8) 13 (3–29)
2006–2008 I–II 40 (39–41) 65 (64–67) 36 (33–38) 64 (60–68) 56 (53–60) 69 (65–73) 33 (29–38) 71 (60–79) 51 (43–59) 67 (57–76)
III–IV 12 (12–13) 35 (31–39) 8 (7–9) 53 (38–64) 19 (17–21) 47 (36–57) 11 (10–13) 56 (35–73) 12 (10–15) 39 (23–55)
2009–2011 I–II 44 (43–45) 70 (68–71) 45 (43–48) 69 (65–72) 55 (52–57) 68 (65–71) 44 (39–49) 77 (70–83) 42 (35–48) 60 (50–68)
III–IV 14 (14–15) 47 (42–51) 9 (8–10) 41 (29–52) 20 (18–22) 53 (42–62) 10 (8–11) 46 (28–63) 11 (9–14) 17 (8–30)
Percent unit change,b P I–II + 6, <  0.001 + 5, < 0.001 + 12, < 0.001 + 5, 0.066 + 3, 0.297 + 6, 0.057 + 10, 0.003 + 11, 0.025 + 4, 0.577 + 9, 0.101
III–IV + 3, <  0.001 + 13, < 0.001 + 1, 0.001 −8, 0.496 + 1, 0.476 + 8, 0.548 + 2, 0.027 + 10, 0.689 + 6, < 0.001 + 5, 0.238
Survival Period Stage USA The Netherlands Belgium Norway Slovenia
Overall Resected Overall Resected Overall Resected Overall Resected Overall Resected
OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI)
36 months 2003–2005 I–II 13 (13–14) 27 (25–29) 8 (7–10) 18 (14–22) 17 (14–21) 24 (19–29) 12 (9–16) 28 (20–36) 9 (6–14) 11 (6–17)
III–IV 2 (2–2) 7 (5–10) 1 (1–2) 14 (6–26) 2 (2–4) 8 (2–16) 1 (1–2) 10 (3–24) 1 (< 1–2) NA
2006–2008 I–II 14 (14–15) 29 (27–30) 12 (10–13) 24 (20–28) 21 (18–23) 28 (25–32) 10 (7–14) 32 (22–41) 19 (14–26) 27 (19–37)
III–IV 2 (2–2) 9 (7–11) 1 (1–1) 11 (5–21) 2 (2–3) 7 (3–14) 2 (1–2) 24 (10–42) 2 (1–3) 12 (4–26)
2009–2011 I–II 17 (16–18) 33 (31–34) 16 (15–18) 29 (26–32) 20 (18–22) 30 (26–33) 15 (12–18) 30 (23–37) 12 (8–16) 17 (11–24)
III–IV 2 (2–2) 11 (9–14) 1 (1–1) 12 (6–21) 2 (1–3) 10 (5–16) 1 (1–2) 14 (5–30) 1 (< 1–1) NA
Percent unit change,b P I–II +4, < 0.001 + 5, < 0.001 + 8, < 0.001 + 11, < 0.001 + 3, 0.076 + 5, 0.035 + 2, 0.025 + 2, 0.205 + 2, 0.468 + 6, 0.069
III–IV + < 1, < 0.001 + 5, < 0.001 + < 1, 0.005 −2, 0.886 −1, 0.285 + 2, 0.317 – < 1, 0.062 +4, 0.785 + < 1, 0.002 NA, NA
60 months 2003–2005 I–II 9 (8–10) 18 (17–20) 4 (3–5) 10 (7–13) 11 (8–14) 16 (12–21) 9 (6–12) 18 (12–25) 7 (3–11) 9 (5–15)
III–IV 1 (1–1) 4 (2–6) 1 (< 1–1) 9 (3–20) 1 (< 1–2) 4 (1–11) 1 (< 1–1) 3 (< 1–15) < 1 (< 1–1) NA
2006–2008 I–II 10 (9–11) 20 (19–21) 7 (6–9) 15 (12–19) 13 (11–15) 18 (15–21) 7 (4–9) 20 (12–28) 9 (5–14) 13 (7–21)
III–IV 1 (1–1) 6 (5–9) < 1 (< 1–1) 6 (2–14) 1 (1–2) 5 (2–11) 1 (< 1–1) 4 (< 1–17) 2 (1–3) 12 (4–26)
2009–2011 I–II NA NA 10 (8–12) 18 (15–21) 12 (10–14) 18 (15–21) 10 (7–13) 20 (14–27) 8 (5–12) 11 (6–17)
III–IV NA NA 1 (< 1–1) 12 (6–21) 1 (< 1–1) 2 (< 1–7) < 1 (< 1–1) NA < 1 (< 1–1) NA
Percent unit change,b P I–II NA, NA NA, NA + 6, < 0.001 + 8, < 0.001 + 1, 0.109 + 2, 0.090 + 1, 0.043 + 2, 0.262 + 2, 0.469 + 2, 0.113
III–IV NA, NA NA, NA + < 1, 0.004 + 3, 0.935 –< 1, 0.290 −2, 0.409 - < 1, 0.069 NA, NA + < 1, 0.002 NA, NA
  1. OS overall survival, NA not available as follow-up was not long enough
  2. aData are shown as survival rate (95% confidence interval) [%]
  3. bPercent changes are shown by comparing average survival of patients diagnosed in 2009–2011 to those in 2003–2005. Significant changes according to P values calculated using the log-rank test are highlighted in bold